A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

@article{Posey1999APT,
  title={A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.},
  author={James A. Posey and Richard Raspet and Ujala Verma and Yashwant M. Deo and Tymen Keller and John Marshall and J. Hodgson and Amitabha Mazumder and Michael J. Hawkins},
  journal={Journal of immunotherapy},
  year={1999},
  volume={22 4},
  pages={371-9}
}
MDX-H210 is a chemically, cross-linked, half-humanized bispecific antibody composed of F(ab') fragment from monoclonal antibody (mAb) H22 that binds to the high-affinity receptor Fc gamma RI and F(ab') of mAb 520C9 that recognizes the erbB-2 (HER2/neu) oncoprotein. In a previous trial, the murine bispecific, MDX-210 at a dose of 7 mg/m2, was well tolerated and activated monocytes and macrophages in vivo in doses as low as 0.35 mg/m2. In our multidose trial, granulocyte-macrophage colony… CONTINUE READING
11 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…